Accelerated Approval: Makena Real-World Evidence Insufficient To Verify Clinical Benefit, CDER Says
Executive Summary
Covis seeks to discuss study proposals and other accelerated approval precedents at still-unscheduled withdrawal hearing; CDER says company’s current RWE proposal is inadequate given its design and the failure of the PROLONG confirmatory clinical trial.
You may also be interested in...
Real-World Evidence: CDER, Covis Flipped The Script For Leveraging Makena Observational Studies
US FDA’s drugs center defended its use of observational studies and randomized trials in other populations to argue that evidence of Makena’s efficacy in preventing preterm birth is lacking; Covis’ expert said observational studies have little to contribute and trials in non-indicated populations are irrelevant.
Makena Randomized, Controlled Trial Proposal Shows Evolution In Covis’ Thinking
Just three years ago, then-sponsor AMAG Pharmaceuticals said another trial of the preterm birth prevention drug in the US would be unethical and infeasible. Now, AMAG parent Covis is proposing to conduct a new study designed to address the shortcomings of the PROLONG trial.
Makena Hearing: Covis Seeks To Skip Question, Likely Negative Vote On Confirmatory Trial Results
By proposing to stipulate that findings from the PROLONG study do not verify Makena’s clinical benefit on neonatal morbidity and mortality from complications of preterm birth, Covis could avoid what would likely be a highly negative vote on the first question posed to the advisory committee at the 17-19 October public hearing on withdrawal of the application.